The risk that the results of post-marketing clinical studies, all-case post-marketing surveillance, and reexamination of regenerative medicine products may affect the maintenance of approval and business performance. The focus is on the fulfilment of post-approval conditions and reexamination, rather than delays in the review before approval is obtained.